Organicell Reports Interim Results of Phase 1/2A Research Program

Stock Information for Organicell Regenerative Medicine Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Organicell Regenerative Medicine Inc

RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Announces 1-for-200 Reverse Stock Split
Organicell Welcomes Howard Golub, MD, PhD As Its New EVP/CSO
Organicell Welcomes Harry Leider, MD, MBA as its New CEO
FINRA Approves Marketplace Name Change to Organicell Regenerative Medicine, Inc. and Trading Symbol Change To "OCEL"
Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using ZofinTM
Organicell Launches Autologous Blood Derived Platform PPX(TM) - Patient Pure X(TM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.